N/A
Manufactured by Alexion Pharmaceuticals, Inc.
17,151 FDA adverse event reports analyzed
Last updated: 2026-04-14
ASFOTASE ALFA is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Alexion Pharmaceuticals, Inc.. The most commonly reported adverse reactions for ASFOTASE ALFA include INJECTION SITE PAIN, INJECTION SITE ERYTHEMA, FATIGUE, PAIN, INJECTION SITE REACTION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ASFOTASE ALFA.
Out of 9,084 classified reports for ASFOTASE ALFA:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 17,151 FDA FAERS reports that mention ASFOTASE ALFA. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include INJECTION SITE PAIN, INJECTION SITE ERYTHEMA, FATIGUE, PAIN, INJECTION SITE REACTION, ARTHRALGIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Alexion Pharmaceuticals, Inc. in connection with ASFOTASE ALFA. Always verify the specific product and NDC with your pharmacist.